EUVIMEDEUVIMED entdecken
Crossref

Australian Group on Antimicrobial Resistance (AGAR) Australian Gram-negative Surveillance Outcome Program (GnSOP) - Bloodstream Infection Annual Report 2022

Jan M Bell, Alicia Fajardo Lubian, Sally R Partridge, Thomas Gottlieb, Jennifer Robson, Jonathan R Iredell, Denise A Daley, Geoffrey W Coombs

Communicable Diseases Intelligence · 2023

DOI: 10.33321/cdi.2023.47.69 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Communicable Diseases Intelligence, 2023. Verfasst von Jan M Bell und 7 weiteren Autor:innen. Beteiligte Einrichtung: Australian Group on Antimicrobial Resistance, Adelaide, South Australia, Australia. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Sepsis. Die Arbeit wurde bisher 5-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The Australian Group on Antimicrobial Resistance (AGAR) performs regular period-prevalence studies to monitor changes in antimicrobial resistance in selected enteric gram-negative pathogens. The 2022 survey was the tenth year to focus on blood stream infections caused by Enterobacterales, and the eighth year where Pseudomonas aeruginosa and Acinetobacter species were included. Fifty-five hospitals Australia-wide participated in 2022. The 2022 survey tested 9,739 isolates, comprising Enterobacterales (8,773; 90.1%), P. aeruginosa (840; 8.6%) and Acinetobacter species (126; 1.3%), using commercial automated methods. The results were analysed using Clinical and Laboratory Standards Institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints (January 2023). Key resistances included resistance to the third-generation cephalosporin ceftriaxone in 12.7%/12.7% (CLSI/EUCAST criteria) of Escherichia coli and in 6.6%/6.6% of Klebsiella pneumoniae complex. Resistance rates to ciprofloxacin were 13.7%/13.7% for E. coli; 7.8%/7.8% for K. pneumoniae complex; 5.3%/5.3% for Enterobacter cloacae complex; and 4.3%/10.0% for P. aeruginosa. Resistance rates to piperacillin-tazobactam were 2.8%/5.9%; 2.9%/8.7%; 18.3%/27.2%; and 6.1%/14.7% for the same four species, respectively. Twenty-nine Enterobacterales isolates from 28 patients were shown to harbour a carbapenemase gene: 18 blaIMP-4; four blaNDM-5; three blaNDM-1; one blaOXA-181; one blaOXA-244; one blaNDM-1 + blaOXA-181; and one blaNDM-5 + blaOXA-181. Transmissible carbapenemase genes were also detected among two Acinetobacter baumannii complex isolates (blaOXA-23) and one P. aeruginosa (blaNDM-1) in the 2022 survey.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Bacterial AgentsSepsisHumansAgarEscherichia coliDrug Resistance, BacterialAustraliaKlebsiella pneumoniaePseudomonas aeruginosa

Stichwörter der Autor:innen

Australian Group on Antimicrobial Resistance (AGAR)antimicrobial resistancebacteraemiagram-negativeEscherichia coliEnterobacterKlebsiella

Substanzen

Anti-Bacterial AgentsAgar

Autor:innen und Institutionen

  • Australian Group on Antimicrobial Resistance, Adelaide, South Australia, Australia.
  • Westmead Institute for Medical Research, Westmead, New South Wales, Australia; University of Sydney, New South Wales, Australia.
  • Westmead Institute for Medical Research, Westmead, New South Wales, Australia; University of Sydney, New South Wales, Australia; Westmead Hospital, Westmead, New South Wales, Australia.
  • University of Sydney, New South Wales, Australia; Department of Microbiology and Infectious Diseases, Concord Hospital, Concord, New South Wales, Australia . thomas.gottlieb@health.nsw.gov.au.
  • Department of Microbiology, Sullivan Nicolaides Pathology, Bowen Hills, Queensland.
  • Westmead Institute for Medical Research, Westmead, New South Wales, Australia; University of Sydney, New South Wales, Australia ; Westmead Hospital, Westmead, New South Wales, Australia.

Zitieren

APA

Bell, J. M., Fajardo Lubian, A., Partridge, S. R., Gottlieb, T., Robson, J., Iredell, J. R., Daley, D. A., & Coombs, G. W. (2023). Australian Group on Antimicrobial Resistance (AGAR) Australian Gram-negative Surveillance Outcome Program (GnSOP) - Bloodstream Infection Annual Report 2022. Communicable Diseases Intelligence. https://doi.org/10.33321/cdi.2023.47.69

Vancouver

Bell JM, Fajardo Lubian A, Partridge SR, Gottlieb T, Robson J, Iredell JR, et al. Australian Group on Antimicrobial Resistance (AGAR) Australian Gram-negative Surveillance Outcome Program (GnSOP) - Bloodstream Infection Annual Report 2022. Communicable Diseases Intelligence. 2023. doi:10.33321/cdi.2023.47.69

BibTeX
@article{Bell2023,
  author = {Bell, Jan M and Fajardo Lubian, Alicia and Partridge, Sally R and Gottlieb, Thomas and Robson, Jennifer and Iredell, Jonathan R and Daley, Denise A and Coombs, Geoffrey W},
  title = {Australian Group on Antimicrobial Resistance (AGAR) Australian Gram-negative Surveillance Outcome Program (GnSOP) - Bloodstream Infection Annual Report 2022},
  journal = {Communicable Diseases Intelligence},
  year = {2023},
  doi = {10.33321/cdi.2023.47.69}
}
Kostenlos starten →